Casodex: Preclinical Studies and Controversies a

  title={Casodex: Preclinical Studies and Controversies a},
  author={B. Furr},
  journal={Annals of the New York Academy of Sciences},
  • B. Furr
  • Published 1995
  • Medicine, Biology
  • Annals of the New York Academy of Sciences
The established treatment for prostate cancer is endocrine manipulation since the growth of a majority of prostate tumors is stimulated by the male sex hormones, androgens. Thus, effective withdrawal of androgens by orchidectomy or estrogen therapy has been the major form of treatment for prostate cancer for several decades. Orchidectomy is unpopular with patients, causes a loss of libido and can result in psychological trauma; since it is ineffective in about one quarter of patients they will… Expand
Treatment of Androgen-Independent Prostate Cancer.
It is indicated that androgen-independent disease may still be dependent on hormonal stimulation, suggesting that hormonally based therapies may provide continued benefit, and radioisotopes such as strontium 89 have been shown to provide effective palliation for a majority of androgens-independent patients. Expand
Molecular action of androgen in the normal and neoplastic prostate.
This chapter discusses the molecular action of androgen in the normal and neoplastic prostate and finds that amino-terminal truncations in rat AR resulted in loss of activity when the steroid- binding domain was present, but the loss was much less severe when the steroids-binding domain was absent also. Expand
Drug Insight: role of the androgen receptor in the development and progression of prostate cancer
  • M. Taplin
  • Medicine
  • Nature Clinical Practice Oncology
  • 2007
The biology of androgen independence and the development of new approaches targeting AR signaling are reviewed herein and may result in important clinical benefits. Expand
Androgen receptor: role and novel therapeutic prospects in prostate cancer
  • M. Taplin
  • Medicine
  • Expert review of anticancer therapy
  • 2008
Compounds in development, such as antiandrogens, lyase inhibitors, heat-shock protein-90 inhibitors, histone deacetylase inhibitors and others, will provide new tools to more effectively reduce ligand, inhibit AR and/or inhibit costimulatory pathways and result in improved clinical outcomes. Expand
Effect of Small Molecules Modulating Androgen Receptor (SARMs) in Human Prostate Cancer Models
In vitro results highlight the antitumor activity of the two novel molecules (R)-9 and (S)-11, making them a potentially attractive option for the treatment of CRPC. Expand
Neural androgen receptor regulation: effects of androgen and antiandrogen.
The results demonstrate that in vivo AR regulation in the brain basically parallels mechanisms proposed from results obtained with transfected cells and cell lines. Expand
Nonsteroidal progesterone receptor ligands with unprecedented receptor selectivity
Compounds in this series, exemplified by RWJ 26819, demonstrate high affinity and unprecedented specificity for the progesterone receptor relative to other steroid hormone receptors, suggesting they could be effectively used in a clinical setting. Expand
Consequences of Mutations in Androgen Receptor Genes: Molecular Biology and Behavior
This chapter reveals the consequences of mutations in androgen receptor genes and the importance of androgens and androgen receptors with regard to the sexual differentiation of the brain and behavior during development. Expand
Regulation of androgen action.
This chapter describes the different aspects of regulation of androgen action, a member of the steroid-thyroid hormone-retinoid-vitamin D superfamily of nuclear receptors (NRs) that function as ligand-activated transcription factors. Expand
Hormones, vitamins, and growth factors in cancer treatment and prevention: A critical appraisal
A critical appraisal of the effects of these drugs is needed because in many cases they provide dramatic results, but in other cases their effects are conflicting. Expand


A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
Treatment with le uprolide and flutamide is superior to treatment with leuprolide alone in patients with advanced prostate cancer, and Symptomatic improvement was greatest during the first 12 weeks of the combined androgen blockade. Expand
Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma.
Casodex, a pure anti- androgen with a relatively long half-life, produces objective and subjective responses similar to those of surgical or pharmacologic castration and is well tolerated, which makes it a strong candidate for consideration as the future anti-androgen of choice in the treatment of advanced prostate cancer. Expand
Hormone therapy of advanced prostate cancer: where we stand today.
Until recently, the treatment of advanced prostatic carcinoma centered around orchiectomy or estrogen administration, but now, LHRH agonists will produce anorchid levels of testosterone with fewer side effects than DES, suggesting combination therapy may produce significant benefits, particularly in patients with minimal disease. Expand
Ocular toxicity of Anandron in patients treated for prostatic cancer.
The availability of a compound such as flutamide that has no side effect other than those due to hypoandrogenicity should greatly facilitate compliance by the patients and the success of the treatment of prostatic cancer. Expand
Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome.
The results suggest that a trial of flutamide withdrawal is justified in an asymptomatic patient with an increasing PSA before treatment with more toxic therapies, and shows the importance of documenting sequential elevations in the marker before enrolling a patient in a clinical trial. Expand
A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia.
Casodex patients tended to obtain more improvement in symptom scores than placebo patients, reaching statistical significance for irritative symptoms at week 24, and even if all patients had side effects, mostly mild, Casodex was well tolerated and patient compliance was excellent. Expand
Antiandrogen ICI 176,334 does not prevent development of androgen insensitivity in S115 mouse mammary tumour cells.
Although a pure antiandrogen in its action on these cells with very low toxicity had no protective effect against loss of cellular or molecular androgen-responsive parameters, the clinical implications for endocrine therapy are discussed. Expand
Safety, side effects and patient acceptance of the antiandrogen Casodex in the treatment of benign prostatic hyperplasia.
Casodex, a new nonsteroidal antiandrogen, was investigated in this double-blind, randomized, placebo-controlled study comprising 28 evaluable patients with benign prostatic hyperplasia, who receivedExpand
[Contraceptive and therapeutic applications of luteinizing hormone releasing hormone (LHRH) analogues].
  • H. Fraser
  • Medicine
  • Sheng zhi yu bi yun = Reproduction and contraception
  • 1987
Using LHRH agonist in the treatment of endometriosis, excessive menstrual bleeding, and uterine fibroid has shown encouraging prospects, and the ability of long term agonist treatment to cause suppression of pituitary and gonadal function can be utilized for contraception. Expand
Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.
Nilutamide and Orchiectomy constitute a more effective treatment for metastatic prostatic cancer than orchiectomy alone, and the adverse effects of nilutamide, usually minor, are outweighed by the significant improvements in most disease measures and progression-free survival. Expand